Review
Version 1
Preserved in Portico This version is not peer-reviewed
Novel Biomarkers in Cutaneous T Cell Lymphomas
Version 1
: Received: 27 December 2022 / Approved: 29 December 2022 / Online: 29 December 2022 (06:41:22 CET)
How to cite: Przybylski, G. K. Novel Biomarkers in Cutaneous T Cell Lymphomas. Preprints 2022, 2022120555. https://doi.org/10.20944/preprints202212.0555.v1 Przybylski, G. K. Novel Biomarkers in Cutaneous T Cell Lymphomas. Preprints 2022, 2022120555. https://doi.org/10.20944/preprints202212.0555.v1
Abstract
Cutaneous T cell lymphomas (CTCLs) are caused by malignant clonal proliferation of skin-tropic T cells. Most patients have an indolent disease course managed with skin-directed therapies, while some entities, or in advanced stages of disease, have aggressive progression and poor survival. To efficiently treat CTCL consistent entity markers are needed to prevent the delay in diagnosis and to provide disease specific treatment to patients. Recently, the introduction of high throughput parallel sequencing methods resulted in identification of numerous genetic and ep-igenetic alterations affecting the transcriptome of CTCL cells. In this review, most relevant genes, including TOX, CADM1, PLS3, DNM3, CXCL13, PD-1, BCL11B and TMEM244 are reported that are specifically expressed in CTCL. Upon verification their specificity and sensitivity in larger studies, their altered expression will be able to be recognized as novel biomarkers, that can im-prove the early diagnosis of CTCL.
Keywords
CTCL; biomarker; TOX; PLS3; CADM1; DNM3; CXCL13; PD-1; BCL11B; TMEM244
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment